Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flavone acetic acid is a synthetic flavonoid compound investigated primarily as an anticancer agent. It exhibits vascular targeting properties and has demonstrated antiproliferative effects on endothelial cells, likely through a superoxide-dependent mechanism that alters tumor vasculature permeability[1][5]. Preclinical studies showed unique antitumor activity, including the ability to induce regression of slow-growing solid tumors in mice by causing vascular collapse prior to tumor regression[5][7]. The precise mechanism of action remains unclear but may involve direct cytotoxicity at high concentrations, immunomodulatory effects (such as stimulation of natural killer cell activity and induction of interferon alpha), and dramatic reduction in tumor blood flow[7]. Flavone acetic acid has been evaluated in phase I clinical trials for cancer but did not demonstrate objective responses in patients[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flavone acetic acid.